<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01647542</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-875_307</org_study_id>
    <secondary_id>U1111-1129-7865</secondary_id>
    <secondary_id>1015011378</secondary_id>
    <nct_id>NCT01647542</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes</brief_title>
  <acronym>GRAND-307</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg Compared With Placebo in Asia Pacific Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of TAK-875 in Asia Pacific
      adults with type 2 diabetes mellitus (T2DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-875. TAK-875 is being tested to treat
      people who have diabetes.

      The study will enroll approximately 750 patients. Participants will be randomly assigned (by
      chance, like flipping a coin) to one of the two treatment groups—which will remain
      undisclosed to the patient and study doctor during the study (unless there is an urgent
      medical need):

        -  TAK-875 25 mg once daily

        -  TAK-875 50 mg once daily

        -  Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has
           no active ingredient

      All participants will be asked to take one tablet at the same time each day throughout the
      study. All participants will be asked to record any time they have low blood sugar symptoms
      in a diary.

      This multi-centre trial will be conducted the Asia Pacific region. The overall time to
      participate in this study is 30 weeks. Participants will make 13 visits to the clinic.

      Due to potential concerns about liver safety, on balance, the benefits of treating patients
      with fasiglifam (TAK-875) do not outweigh the potential risks.

      For this reason, Takeda has decided voluntarily to terminate the development activities for
      fasiglifam.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to potential concerns about liver safety (See Detailed Description)
  </why_stopped>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 24 relative to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HbA1c &lt;7% at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose From Baseline to Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The change between the fasting plasma glucose value collected at Week 24 relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-hour Postprandial Glucose (PPG) Following Oral Glucose Tolerance Test (OGTT) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The change between the value of glucose after a meal, measured following OGTT collected at Week 24 relative to baseline. Oral glucose tolerance test measures glucose, insulin, and C-peptide through blood samples drawn at 0, 30, 60, 90, and 120 minutes following consumption of a 75 gram (g) glucose beverage.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">393</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>TAK-875 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-875 25 mg tablets, orally, once daily for up to 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-875 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-875 50 mg tablets, orally, once daily for up to 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-875 placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-875</intervention_name>
    <description>TAK-875 tablets</description>
    <arm_group_label>TAK-875 25 mg</arm_group_label>
    <arm_group_label>TAK-875 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-875 Placebo</intervention_name>
    <description>TAK-875 placebo-matching tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the opinion of the investigator, the patient is capable of understanding and
             complying with protocol requirements.

          2. The patient or, when applicable, the patient's legally acceptable representative signs
             and dates a written, informed consent form and any required privacy authorization
             prior to the initiation of any study procedures.

          3. Male or female, aged at least 18 years or over the legal age of consent in countries
             where that is greater than 18 years, with a historical diagnosis of T2DM.

          4. Has an HbA1c of 7.0% to 10.0%, inclusive at screening, and has been treated with diet
             and exercise for at least 3 months.

          5. Has a body mass index (BMI) of ≤45 kg/m^2 at screening.

          6. Patients regularly using, non-excluded medications, must be on a stable dose for at
             least 4 weeks prior to Screening. However, PRN (as needed) use of prescription or
             over-the-counter medication is allowed at the discretion of the investigator.

          7. A female of childbearing potential who is sexually active with a nonsterilized male
             partner agrees to routinely use adequate contraception from signing of the informed
             consent throughout the duration of the study and for 30 days after the last dose of
             study drug.

          8. Is able and willing to monitor glucose with a home glucose monitor and consistently
             record his or her own blood glucose concentrations and complete subject diaries.

        Exclusion Criteria:

          1. Is unable to understand the official language (verbal or written) of the country for
             which a certified translation of the approved informed consent is available.

          2. Is an immediate family member, study site employee, or is in a dependent relationship
             with a study site employee who is involved in conduct of this study (eg, spouse,
             parent, child, or sibling; biological or legally adopted) or may consent under duress.

          3. Has hemoglobin a level ≤12 g/dL (≤120 g/L) (males) and ≤10 g/dL (≤100 g/L) (females)
             at the Screening Visit.

          4. Has a history of any hemoglobinopathy that may affect determination of HbA1c.

          5. Donated or received any blood products within 12 weeks prior to Screening or is
             planning to donate blood during the study.

          6. Has systolic blood pressure ≥160 mm Hg or diastolic pressure ≥95 mm Hg at Screening or
             Baseline (If the patient meets this exclusion criterion, the assessment may be
             repeated once at least 30 minutes after initial measurement and decision will be made
             based on the second measurement).

          7. Had coronary angioplasty, coronary stent placement, coronary bypass surgery,
             myocardial infarction, unstable angina pectoris, clinically significant abnormal
             electrocardiogram, cerebrovascular accident or transient ischemic attack within 3
             months prior or at Screening.

          8. Has a serum creatinine level of ≥1.5 mg/dL (males) and ≥1.4 mg/dL (females) and/or
             estimated glomerular filtration rate (GFR) &lt;60 mL/min/1.73m^2 at Screening.

          9. Has uncontrolled thyroid disease.

         10. Has a history of laser treatment for proliferative diabetic retinopathy within 6
             months prior to Screening.

         11. Has a history or treatment for diabetic gastric paresis, gastric banding, or gastric
             bypass surgery.

         12. Has alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels
             &gt;2.0x the upper limit of normal range (ULN) at Screening.

         13. Has a total bilirubin level greater than the ULN at Screening. Exception: if a patient
             has documented Gilbert's Syndrome, they will be allowed with an elevated bilirubin
             level per the investigator's discretion.

         14. Has a known history of infection with human immunodeficiency virus (HIV), Hepatitis B
             virus (HBV), or Hepatitis C virus (HCV).

         15. If a patient has no known history of HBV infection, then a HBV Screening test panel
             should be done. If the test is positive and there is clinical manifestation of active
             infection per Investigator's diagnosis, then the patient should be excluded. In
             addition, if the patient is considered to need antiviral treatment, the patient should
             be excluded. (If the test results indicate only an hepatitis B surface antigen (HBsAg)
             carrier without any clinical manifestation of active infection, and no antiviral
             treatment is needed, then the patient could be enrolled provided all other criteria
             are met.)

         16. Has a history of cancer that has been in remission for &lt;5 years prior to Screening. A
             history of basal cell carcinoma or stage 1 squamous cell carcinoma of the skin is
             allowed.

         17. Has received any investigational compound within 30 days prior to Screening or has
             received &gt;7 days of any antidiabetic agent within 3 months prior to Screening.

         18. Has received TAK-875 in a previous clinical study.

         19. Has a history of hypersensitivity, allergies or has had an anaphylactic reaction(s) to
             any component of TAK-875.

         20. Has a history of drug abuse (defined as illicit drug use) or a history of alcohol
             abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per
             day) within 2 years prior to Screening.

         21. Received excluded medications prior to Screening or is expected to receive excluded
             medications.

         22. If female, is pregnant (confirmed by laboratory testing, ie, serum/urine human
             chorionic gonadotropin (hCG), in females of childbearing potential) or lactating or
             intending to become pregnant before, during, or within 1 month after participating in
             this study; or intending to donate ova during such time period.

         23. If male, intends to donate sperm during the course of this study or for 30 days after
             final study medication dose.

         24. Has any other physical or psychiatric disease or condition that in the judgment of the
             investigator may affect life expectancy or may make it difficult to successfully
             manage and follow the subject according to the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brookvale</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mosman</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woy Woy</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing,P.R.</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chenzhou</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suzhou City</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changchun City, Jilin Province</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heilongjiang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotorua</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2012</study_first_posted>
  <results_first_submitted>July 22, 2015</results_first_submitted>
  <results_first_submitted_qc>July 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2015</results_first_posted>
  <last_update_submitted>October 15, 2015</last_update_submitted>
  <last_update_submitted_qc>October 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 59 investigative sites in Australia, China, the Republic of Korea, New Zealand and Taiwan from 30 July 2012 to 18 March 2014.</recruitment_details>
      <pre_assignment_details>Participants with a historical diagnosis of type 2 diabetes mellitus (T2DM) who were inadequately controlled when treated with only diet, exercise and any antidiabetic agent for less than or equal to (&lt;=) 7 days within 12 weeks prior to Screening, were enrolled in 1 of 3 treatment groups: placebo; fasiglifam 25 milligram (mg); fasiglifam 50 mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Fasiglifam placebo-matching tablets, orally, once daily, for up to 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Fasiglifam 25 mg</title>
          <description>Fasiglifam 25 mg, tablets, orally, once daily, for up to 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Fasiglifam 50 mg</title>
          <description>Fasiglifam 50 mg, tablets, orally, once daily, for up to 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="131"/>
                <participants group_id="P3" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Major Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Termination</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The randomized set included all participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Fasiglifam placebo-matching tablets, orally, once daily, for up to 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Fasiglifam 25 mg</title>
          <description>Fasiglifam 25 mg, tablets, orally, once daily, for up to 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Fasiglifam 50 mg</title>
          <description>Fasiglifam 50 mg, tablets, orally, once daily, for up to 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="131"/>
            <count group_id="B2" value="131"/>
            <count group_id="B3" value="131"/>
            <count group_id="B4" value="393"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.7" spread="12.41"/>
                    <measurement group_id="B2" value="55.1" spread="11.89"/>
                    <measurement group_id="B3" value="53.1" spread="10.96"/>
                    <measurement group_id="B4" value="53.6" spread="11.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than (&lt;) 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to (&gt;=) 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>Kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.00" spread="4.348"/>
                    <measurement group_id="B2" value="25.97" spread="3.989"/>
                    <measurement group_id="B3" value="26.12" spread="3.516"/>
                    <measurement group_id="B4" value="26.03" spread="3.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c) Category</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 8.5 percent (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 8.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Enrollment by Region</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan, Province of China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <description>For this measure, number of participants evaluable were 125, 122, 124 for each arm respectively.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.293" spread="3.063"/>
                    <measurement group_id="B2" value="3.499" spread="3.64"/>
                    <measurement group_id="B3" value="2.182" spread="2.782"/>
                    <measurement group_id="B4" value="2.652" spread="3.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c at Week 24</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 24 relative to baseline.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full Analysis Set (FAS) included of all randomized participants who received at least 1 dose of double blind study medication. Only participants with a baseline and at least 1 post-baseline value were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Fasiglifam placebo-matching tablets, orally, once daily, for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fasiglifam 25 mg</title>
            <description>Fasiglifam 25 mg, tablets, orally, once daily, for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fasiglifam 50 mg</title>
            <description>Fasiglifam 50 mg, tablets, orally, once daily, for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Week 24</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 24 relative to baseline.</description>
          <population>Full Analysis Set (FAS) included of all randomized participants who received at least 1 dose of double blind study medication. Only participants with a baseline and at least 1 post-baseline value were included.</population>
          <units>Percentage of Glycosylated Hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 120, 124, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.99" spread="0.104"/>
                    <measurement group_id="O2" value="7.94" spread="0.101"/>
                    <measurement group_id="O3" value="7.91" spread="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24 (n= 52, 61, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.101"/>
                    <measurement group_id="O2" value="-0.67" spread="0.097"/>
                    <measurement group_id="O3" value="-0.87" spread="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Assuming a standard deviation of 0.9% in change from baseline in HbA1c to Week 24 and a dropout rate of 15%, 210 participants per group provided at least 95% power to detect a treatment difference of 0.5% between treatment arms at a 2–sided significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Stepwise Comparison: 1) TAK-875 50 mg versus (vs.) placebo, 2) TAK-875 25 mg vs. placebo. Step 2 was performed only if p-value at step 1 was &lt;=0.050.</p_value_desc>
            <method>Mixed Model Repeated Measures</method>
            <method_desc>Treatment, country, visit, and visit-by-treatment interaction as fixed factors, baseline value as covariate.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.126</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.27</ci_lower_limit>
            <ci_upper_limit>-0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming a standard deviation of 0.9% in change from baseline in HbA1c to Week 24 and a dropout rate of 15%, 210 participants per group provided at least 95% power to detect a treatment difference of 0.5% between treatment arms at a 2–sided significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Stepwise Comparison: 1) TAK-875 50 mg versus (vs.) placebo, 2) TAK-875 25 mg vs. placebo. Step 2 was performed only if p-value at step 1 was &lt;=0.050.</p_value_desc>
            <method>Mixed Model Repeated Measures</method>
            <method_desc>Treatment, country, visit, and visit-by-treatment interaction as fixed factors, baseline value as covariate.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.126</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HbA1c &lt;7% at Week 24</title>
        <time_frame>Week 24</time_frame>
        <population>FAS included of all randomized participants who received at least 1 dose of double blind study medication. Only Participants with a baseline and at least 1 post baseline value were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Fasiglifam placebo-matching tablets, orally, once daily, for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fasiglifam 25 mg</title>
            <description>Fasiglifam 25 mg, tablets, orally, once daily, for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fasiglifam 50 mg</title>
            <description>Fasiglifam 50 mg, tablets, orally, once daily, for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HbA1c &lt;7% at Week 24</title>
          <population>FAS included of all randomized participants who received at least 1 dose of double blind study medication. Only Participants with a baseline and at least 1 post baseline value were included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="42.7"/>
                    <measurement group_id="O3" value="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Treatment and baseline HbA1c as explanatory variables.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.99</ci_lower_limit>
            <ci_upper_limit>10.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Treatment and baseline HbA1c as explanatory variables.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.81</ci_lower_limit>
            <ci_upper_limit>6.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose From Baseline to Week 24</title>
        <description>The change between the fasting plasma glucose value collected at Week 24 relative to baseline.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS included of all randomized participants who received at least 1 dose of double blind study medication. Only participants with a baseline and at least 1 post baseline value were included</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Fasiglifam placebo-matching tablets, orally, once daily, for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fasiglifam 25 mg</title>
            <description>Fasiglifam 25 mg, tablets, orally, once daily, for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fasiglifam 50 mg</title>
            <description>Fasiglifam 50 mg, tablets, orally, once daily, for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose From Baseline to Week 24</title>
          <description>The change between the fasting plasma glucose value collected at Week 24 relative to baseline.</description>
          <population>FAS included of all randomized participants who received at least 1 dose of double blind study medication. Only participants with a baseline and at least 1 post baseline value were included</population>
          <units>Milligram per deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n =129, 127, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.4" spread="4.74"/>
                    <measurement group_id="O2" value="152.4" spread="4.67"/>
                    <measurement group_id="O3" value="149.7" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24 (n = 51, 58, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="3.59"/>
                    <measurement group_id="O2" value="-20.6" spread="3.42"/>
                    <measurement group_id="O3" value="-20.4" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Mixed Model Repeated Measures</method>
            <method_desc>Treatment, country, visit, and visit-by-treatment interaction as fixed factors, baseline value covariate.</method_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-35.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.2</ci_lower_limit>
            <ci_upper_limit>-26.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>Mixed Model Repeated Measures</method>
            <method_desc>Treatment, country, visit, and visit-by-treatment interaction as fixed factors, baseline value as covariate.</method_desc>
            <param_type>Least Squares mean Difference</param_type>
            <param_value>-35.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.3</ci_lower_limit>
            <ci_upper_limit>-27.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-hour Postprandial Glucose (PPG) Following Oral Glucose Tolerance Test (OGTT) at Week 24</title>
        <description>The change between the value of glucose after a meal, measured following OGTT collected at Week 24 relative to baseline. Oral glucose tolerance test measures glucose, insulin, and C-peptide through blood samples drawn at 0, 30, 60, 90, and 120 minutes following consumption of a 75 gram (g) glucose beverage.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS included of all randomized participants who received at least 1 dose of double blind study medication. Only participants with a baseline and at least 1 post-baseline value were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Fasiglifam placebo-matching tablets, orally, once daily, for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Fasiglifam 25 mg</title>
            <description>Fasiglifam 25 mg, tablets, orally, once daily, for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Fasiglifam 50 mg</title>
            <description>Fasiglifam 50 mg, tablets, orally, once daily, for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-hour Postprandial Glucose (PPG) Following Oral Glucose Tolerance Test (OGTT) at Week 24</title>
          <description>The change between the value of glucose after a meal, measured following OGTT collected at Week 24 relative to baseline. Oral glucose tolerance test measures glucose, insulin, and C-peptide through blood samples drawn at 0, 30, 60, 90, and 120 minutes following consumption of a 75 gram (g) glucose beverage.</description>
          <population>FAS included of all randomized participants who received at least 1 dose of double blind study medication. Only participants with a baseline and at least 1 post-baseline value were included.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.3" spread="21.69"/>
                    <measurement group_id="O2" value="121.2" spread="22.76"/>
                    <measurement group_id="O3" value="129.0" spread="18.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="24.58"/>
                    <measurement group_id="O2" value="-21.2" spread="25.98"/>
                    <measurement group_id="O3" value="9.6" spread="21.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.846</p_value>
            <p_value_desc>No multiplicity adjustments.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment and country as fixed factors and baseline value as covariate.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>5.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>29.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.9</ci_lower_limit>
            <ci_upper_limit>69.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.427</p_value>
            <p_value_desc>No multiplicity adjustments.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment and country as fixed factors and baseline value as covariate.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-24.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>30.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-90.1</ci_lower_limit>
            <ci_upper_limit>40.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment ­emergent adverse events are adverse events that started after the first dose of double­ blind study drug and no more than 30 days after the last dose of double blind study drug.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Fasiglifam placebo-matching tablets, orally, once daily, for up to 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Fasiglifam 25 mg</title>
          <description>Fasiglifam 25 mg, tablets, orally, once daily, for up to 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Fasiglifam 50 mg</title>
          <description>Fasiglifam 50 mg, tablets, orally, once daily, for up to 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Insulin resistance</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

